Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), BioMarin Pharmaceutical (BMRN – Research Report) and Ionis Pharmaceuticals (IONS – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma (ASND)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Ascendis Pharma, with a price target of $262.00. The company’s shares closed last Monday at $231.03.
According to TipRanks.com, Ahmad is a 2-star analyst with an average return of
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $293.23, a 29.7% upside from current levels. In a report issued on March 15, Jefferies also initiated coverage with a Buy rating on the stock with a $290.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
BioMarin Pharmaceutical (BMRN)
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on BioMarin Pharmaceutical yesterday and set a price target of $85.00. The company’s shares closed last Monday at $57.43.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $89.13, representing a 57.2% upside. In a report issued on March 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $85.00 price target.
Ionis Pharmaceuticals (IONS)
In a report issued on March 12, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $110.00. The company’s shares closed last Monday at $72.34.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
Currently, the analyst consensus on Ionis Pharmaceuticals is a Strong Buy with an average price target of $95.54, representing a 33.5% upside. In a report issued on February 25, William Blair also maintained a Buy rating on the stock.
